Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 145,000 shares at $17.97 ($2.6M) on 2015-01-28, disclosed to the SEC on 2015-01-30.
Scheduled sale ($2.6M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.97 | 72,011 | $1.3M | 49.4% |
| 2 | $18.69 | 12,989 | $243K | 9.3% |
| 3 | $17.77 | 33,773 | $600K | 22.9% |
| 4 | $18.40 | 26,227 | $483K | 18.4% |
| Total | $18.07 avg | 145,000 | $2.6M | 100% |
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |